SEC Comment Letter 0000000000-22-012442 to Larimar Therapeutics, Inc. (LRMR) (CIK 0001374690) (LRMR)
Larimar Therapeutics, Inc. (LRMR) (CIK 0001374690)
Date: Nov. 16, 2022 · CIK: 0001374690 · Accession: 0000000000-22-012442
AI Filing Summary & Sentiment
File numbers found in text: 333-268312
Letter
United States securities and exchange commission logo November 16, 2022 Mr. Michael Celano Chief Financial Officer Larimar Therapeutics, Inc. Three Bala Plaza East, Suite 506 Bala Cynwyd, PA 19004 Re:Larimar Therapeutics, Inc. Registration Statement on Form S-3 Filed November 10, 2022 File No. 333-268312 Dear Mr. Michael Celano: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Cindy Polynice at 202-551-8707 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jennifer Porter, Esq.
Show Raw Text
United States securities and exchange commission logo
November 16, 2022
Mr. Michael Celano
Chief Financial Officer
Larimar Therapeutics, Inc.
Three Bala Plaza East, Suite 506
Bala Cynwyd, PA 19004
Re:Larimar Therapeutics, Inc.
Registration Statement on Form S-3
Filed November 10, 2022
File No. 333-268312
Dear Mr. Michael Celano:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Cindy Polynice at 202-551-8707 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jennifer Porter, Esq.